EKF Diagnostics Holdings plc (LON:EKF) insider Adam Reynolds sold 500,000 shares of the stock in a transaction that occurred on Friday, April 30th. The stock was sold at an average price of GBX 73 ($0.95), for a total value of £365,000 ($476,874.84).

Shares of LON EKF opened at GBX 71 ($0.93) on Wednesday. The firm has a market cap of £323.05 million and a P/E ratio of 29.58. The company has a current ratio of 2.26, a quick ratio of 1.83 and a debt-to-equity ratio of 2.02. EKF Diagnostics Holdings plc has a 1-year low of GBX 38.40 ($0.50) and a 1-year high of GBX 83 ($1.08). The business’s 50 day moving average is GBX 75.14 and its 200-day moving average is GBX 69.87.

The company also recently announced a dividend, which will be paid on Wednesday, December 1st. Stockholders of record on Wednesday, November 3rd will be paid a dividend of GBX 1.10 ($0.01) per share. The ex-dividend date of this dividend is Wednesday, November 3rd. This represents a dividend yield of 1.51%. This is a positive change from EKF Diagnostics’s previous dividend of $1.00. EKF Diagnostics’s dividend payout ratio (DPR) is 0.42%.

EKF Diagnostics Company Profile

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, and Africa. It offers DiaSpect and DiaSpect T hemoglobin analyzers; DiaSpect Hemoglobin T Low to determine low levels of hemoglobin in plasma and serum specimens, aqueous solutions, or stored or banked erythrocytes; Hemo Control, a point-of-care hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples.

Featured Story: How to Invest in Stocks with Increasing Dividends

Receive News & Ratings for EKF Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EKF Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.